Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
24 junio 2026
Marc Dalessio wins the Herbert Smith Freehills Kramer Portrait Award 2026 for his captivating portrait of neighbour
Marc Dalessio has won first prize in the prestigious Herbert Smith Freehills Kramer Portrait Award 2026 for his portrait Jean-Denis
23 junio 2026
Herbert Smith Freehills Kramer advises the sole sponsor on HJ Science’s Hong Kong IPO
Leading global law firm Herbert Smith Freehills Kramer has advised CITIC Securities (Hong Kong) Limited as the sole sponsor on HJ Science Co., Ltd. …
23 junio 2026
Driving credible climate action: HSF Kramer supports SBTi’s Corporate Net Zero Standard 2.0
Leading global law firm Herbert Smith Freehills Kramer has provided strategic legal support to the Science Based Targets initiative (SBTi) in connection …